Start here if you're new
what it is
Envista sells dentists the tools, supplies, imaging gear, and aligners they need to keep chairs full.
how it gets paid
Last year Envista made $2.7B in revenue. dental implants was the main engine at $0.70B, or 26% of sales.
why it's growing
Revenue grew 8.3% last year. Broad-based growth, cost cuts, and efficiency gains helped.
what just happened
Envista's latest quarter showed revenue of $750.6M and EPS of $0.38, ahead of the $0.22 estimate.
At a glance
B+ balance sheet — decent shape, but not bulletproof
10/100 earnings predictability — expect surprises
80.2x trailing p/e — you're paying up for this one
6.5% return on capital — nothing to write home about
xvary composite: 54/100 — below average
What they do
Envista sells dentists the tools, supplies, imaging gear, and aligners they need to keep chairs full.
Dentists do not buy one-off gadgets. They buy systems. Envista sells implants, orthodontics, imaging, software, and consumables across more than 30 dental brands, so one sale can turn into years of repeat orders. With 12,300 employees and a 54.7% gross margin, customers are paying for workflow, not just hardware.
How they make money
$2.7B
annual revenue · their business grew +8.3% last year
dental implants
$0.70B
orthodontics
$0.55B
digital imaging & software
$0.45B
restorative & infection prevention
$0.60B
instruments, prosthetics, cements
$0.40B
The products that matter
broad dental equipment portfolio
core dental brands
30+ brands · $2.7B company revenue
this is the scale anchor. over 30 brands produced $2.7B in annual revenue, which gives Envista distribution reach even if the margin profile stays modest.
scale
clear aligner orthodontics
spark aligners
turned profitable
management highlighted that Spark turned profitable after cost cuts and efficiency gains. that's important because margin improvement matters more here than another revenue slogan.
margin lever
digital imaging and workflow tools
Dexis + new launches
Q3 sales +11.5%
new launches like Spark Jr. and Dexis Imprevo IOS were cited as contributors when third-quarter 2025 sales climbed 11.5% from a year ago. product cadence still matters.
launch risk
Key numbers
80.2x
trailing p/e
P/E (price divided by trailing earnings) → what investors pay for past profit → so what: you are paying 80.2 years of trailing earnings for a company that made just $0.30 in 2025 EPS.
$1.4B
long-term debt
Long-term debt → money owed beyond one year → so what: at 27% of capital, debt is large enough to limit how much patience you get if demand softens.
17.0%
operating margin
Operating margin → revenue left after running the business → so what: Envista keeps 17 cents from each sales dollar before interest and taxes.
6.5%
return on capital
Return on capital → profit earned on the money tied up in the business → so what: 6.5% is modest for a company priced like a clean comeback.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 55 / 100
- long-term debt $1.4B (27% of capital)
- net profit margin 9.4% — keeps 9 cents of every dollar in revenue
- return on equity 8% — $0.08 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in NVST 3 years ago → it's now worth $6,360.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Envista's latest quarter showed revenue of $750.6M and EPS of $0.38, ahead of the $0.22 estimate.
Broad-based growth, cost cuts, and efficiency gains helped. Management also said the Spark aligner unit turned profitable, which gave the turnaround story actual math.
$750.6M
revenue
$0.38
eps
54.7%
gross margin
the number that mattered
The $0.38 EPS mattered most because it beat the $0.22 estimate by 72.73%, showing cost control is finally visible in reported profit.
-
envista holdings has been benefiting from healthy sales momentum of late.
-
the maker of dental equipment/supplies had another round of solid business activity, with third-quarter 2025 sales climbing 11.5%, vs. prior year.core sales growth was strong across all main segments, bolstered by new product launches like spark jr. and dexis imprevo ios (intraoral scanner).
-
this, along with cost cuts and efficiency gains, which enabled the spark aligner unit to turn profitable, helped expand the operating margin.
-
but miscellaneous charges led to a loss.
-
the fourth quarter likely saw improvement, though.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is sales momentum fading before margins are fixed.
med
dental demand cools
Envista just put up $2.7B in annual revenue after 38.1% growth, but clinics can delay equipment purchases and orthodontic spending when conditions soften.
with only a 6.0% net margin, a slowdown in ordering would hit earnings harder than revenue.
med
Spark improvement fades
Spark aligners only recently turned profitable through cost cuts and efficiency gains. if that improvement stalls, one of the clearest margin-repair stories on the page goes with it.
that matters because the stock still trades at 80.2x trailing earnings and needs better profitability, not just better headlines.
med
new launches don't scale
management pointed to Spark Jr. and Dexis Imprevo IOS as recent demand drivers. if new products stop carrying growth, the rebound can flatten quickly.
that would pressure the path from $2.7B in revenue toward the $3B estimate the street is using.
med
valuation compresses first
the stock trades at $24.05 while the analyst midpoint shown here is $21, and earnings predictability is only 10 / 100. that's not much room for a miss.
even if the business stays stable, the multiple can do the damage.
this is a $2.7B revenue business with a 6.0% net margin and 80.2x trailing earnings. that combination leaves very little cushion.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
profit has to start catching up to revenue
the street sees revenue reaching $3B and EPS hitting $0.80. if sales grow and earnings still lag, the multiple becomes the problem.
trend
Spark profitability holding
Spark turning profitable is one of the few clean positives in the recent update. you want that to remain true next quarter.
risk
valuation versus reality
80.2x trailing earnings and a $21 midpoint target below the stock price mean expectations still need to be earned.
next check
whether Q4 was the start of a cleaner year
Q4 printed $0.22 EPS on $670M in revenue. the next report needs to show that wasn't just one tidy quarter inside a messy year.
Analyst rankings
short-term outlook
average
momentum score 3. in human-speak, analysts see a stock moving with the market, not leading it.
risk profile
average
stability score 3. this is middle-of-the-pack risk, not a bunker stock and not a chaos trade.
chart momentum
average
technical score 3. the chart is not screaming anything dramatic right now.
earnings predictability
10 / 100
earnings predictability 10 / 100. translation: reported results can get messy fast, so a premium multiple carries extra risk.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 159 buyers vs. 134 sellers in 3q2025. total institutional holdings: 0.2B shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$11
$30
$24
current price
$21
target midpoint · 13% from current · 3-5yr high: $45 (+85% · 17% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive